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Abstract
Background: In randomized, controlled trials of open-angle glaucoma (OAG) or ocular hypertension (OHT),
bimatoprost 0.01 % improved tolerability while retaining the intraocular pressure (IOP)-lowering efficacy of
bimatoprost 0.03 %. Given geographic/racial differences in glaucoma presentation, the APPEAL study assessed the
occurrence and severity of hyperemia produced by bimatoprost 0.01 %, and its efficacy, in the Taiwanese clinical
setting.
Methods: In this multicenter, open-label, observational study, treatment-naïve and previously treated patients with
OHT or OAG received once-daily bimatoprost 0.01 % for 12 weeks. Hyperemia (primary endpoint) was graded at
baseline, week 6, and week 12 using a photonumeric scale (0, +0.5, +1, +2, +3), grouped (≤ +1, none to mild; ≥ +2,
moderate to severe), and reported as unchanged from baseline, improved, or worsened. IOP assessments followed
the same schedule. Supplemental efficacy analyses were conducted based on previous therapies.
Results: The intent-to-treat population (N = 312) included treatment-naïve (13.5 %) and previously treated (86.5 %)
patients; mean age was 53.3 years. At baseline, 46.3 % of previously treated patients were receiving prostaglandin
analog (PGA) monotherapy. At week 12, 91.2 %, 5.9 %, and 2.9 % of treatment-naïve patients exhibited unchanged,
worsened, and improved hyperemia from baseline, respectively; 77.9 %, 12.9 %, and 9.2 % of previously treated
patients showed no change, worsening, and improvement, respectively. There were no statistically significant shifts
in hyperemia severity in either group, or in subgroups based on previous use of any PGA, any non-PGA, latanoprost, or
travoprost monotherapies. In treatment-naïve patients, mean IOP reduction from baseline (18.0 ± 3.8 mm Hg) was 3.6
mm Hg at week 12 (P < 0.0001); 83.3 % had baseline IOP ≤ 21 mm Hg. In previously treated patients, mean additional
IOP reduction from baseline (17.8 ± 3.9 mm Hg) was 2.6 mm Hg (P < 0.0001); similar results were observed in patient
subgroups based on previous therapies.
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Conclusions: In the Taiwanese clinical setting, bimatoprost 0.01 % provided significant IOP lowering in treatment-naïve
patients (regardless of baseline IOP) and previously treated patients (even those with relatively low IOP on other
therapies), while causing no significant changes in hyperemia from baseline.
Trial registration: Clinicaltrials.gov NCT01814761. Registered 18 March 2013.
Keywords: Glaucoma, Normal-tension glaucoma, Ocular hypertension, Intraocular pressure, Hyperemia, Prostaglandin
analog, Prostamide, Bimatoprost
Background
Glaucoma is second only to cataract as a leading cause of
blindness worldwide [1, 2], and because the burden in-
creases substantially with advanced disease [3–5], early
detection and treatment is important. In addition, the
characteristics and prevalence of glaucoma have been
shown to vary with geography and race [6–11], emphasiz-
ing the need for clinical studies and management pro-
grams adapted to local populations [12]. For example,
open-angle glaucoma (OAG) characterized by intraocular
pressure (IOP) ≤ 21 mm Hg (i.e., normal-tension glaucoma
[NTG]) is much more common in patients in Asian coun-
tries than Western ones [13]. A Korean study of adults over
50 years of age indeed showed that NTG accounted for
94.4 % of all OAG cases [14]. Similarly, another Korean
study showed that 75.3 % of patients with OAG had
baseline IOP ≤ 21 mm Hg [15]. However, whether
OAG is associated with elevated or normal IOP, treat-
ment options remain limited because the underlying
mechanisms have yet to be elucidated. Current man-
agement of OAG relies on topical IOP-lowering
agents [16, 17], and prostaglandin analogs (PGAs)/
prostamides are often preferred as first-line therapy
owing to their efficacy, safety, and convenience of use
(once daily) [17–19]. In Taiwan, however, the National
Health Insurance Administration reserves them for
use as second-line therapy [20, 21].
The prostamide bimatoprost 0.03 % (Lumigan® 0.03 %;
Allergan plc, Irvine, CA, USA) is an effective topical treat-
ment with superior IOP-lowering effects (compared with
other PGA monotherapies) and a favorable tolerability
profile with long-term use [22–25]. Importantly, clinical
studies have also demonstrated its efficacy and tolerability
in patients with NTG [26–30]. Nonetheless, some patients
experience adverse events (AEs) when treated with bima-
toprost 0.03 %, the most common being conjunctival
hyperemia. Considering that AEs experienced chronic-
ally can lead to nonadherence to therapy [31, 32] and
impact disease progression [33, 34], bimatoprost
0.01 % (Lumigan® 0.01 %; Allergan plc, Irvine, CA,
USA) [35] was developed and shown to improve
tolerability while retaining the IOP-lowering efficacy
of bimatoprost 0.03 % in clinical studies of patients
with elevated IOP due to OAG or ocular hyperten-
sion (OHT) [36–39].
Given the regional differences in glaucoma presenta-
tion and treatment guidelines mentioned above [40], the
Asia Pacific Patterns from Early Access of Lumigan
0.01 % study in Taiwan (APPEAL Taiwan) evaluated the
occurrence and severity of hyperemia produced by bima-
toprost 0.01 % monotherapy, as well as its IOP-lowering
effects, in patients with OHT or OAG, including NTG,
seen in the Taiwanese clinical practice setting.
Methods
Study design
This 12-week, open-label, noncomparative, observational
study of bimatoprost 0.01 % in consecutive patients with
OAG (including NTG) or OHT (ClinicalTrials.gov iden-
tifier: NCT01814761, registered on March 18, 2013) was
conducted between May 2013 and August 2014, in ac-
cordance with the Guidelines for Good Clinical Practice
and all applicable Taiwanese laws.
Study population
Eligible patients were at least 20 years of age, treatment-
naïve or previously treated, and had been diagnosed be-
fore screening with OHT or OAG (including NTG), ac-
cording to standard of care in the treating physician’s
practice. OAG was defined as an eye with glaucomat-
ous optic nerve head change and corresponding glau-
comatous visual field defects, and the decision to
prescribe topical bimatoprost 0.01 % was made by
the treating physician prior to, and without consider-
ation of study participation (per standard of care).
Key exclusion criteria included a history of bimato-
prost 0.01 % use; contraindications to bimatoprost
0.01 % use; hypersensitivity to any PGA or compo-
nent of the study medication; concomitant use of
topical, periorbital, intravitreal, or systemic steroid
within 3 months of study initiation, or anticipated
use during the study; and presence of any other ab-
normal ocular condition or symptom preventing
study participation.
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Study treatment
Bimatoprost 0.01 % was provided by Allergan Singapore
Pte Ltd. At the baseline visit, patients were instructed
to instill 1 drop of medication in the study eye each
evening (at approximately 8 PM). If both eyes were eli-
gible for inclusion, both were treated, but the eye with
the higher baseline IOP was included in the analysis. If
both eyes had identical baseline IOP, the right eye was
designated as study eye. There was no washout of
previous IOP-lowering medications prior to initiation
of study treatment.
Outcomes and analyses
All outcomes were measured at approximately the same
time of day at baseline, and weeks 6 and 12. The primary
outcome variables were the occurrence and severity of
ocular hyperemia at week 12, assessed and graded using
a standard photonumeric bulbar conjunctival hyperemia
grading scale: 0 (none; normal); +0.5 (trace; trace flush,
reddish pink); +1 (mild; mild flush, reddish color); +2
(moderate; bright red color); and +3 (severe; deep, bright
diffuse redness). Hyperemia grading was then collapsed
into 2 categories: none to mild (i.e., 0 to +1) and moder-
ate to severe (i.e., +2 and +3), as described by other
groups [15, 38, 41, 42], and the shift in hyperemia sever-
ity/grading from baseline at weeks 6 and 12 was re-
ported as improved, unchanged, or worsened [38].
The secondary outcome variables included the change
in IOP from baseline (based on Goldmann applanation to-
nometry performed per standard of care in the treating
physician’s practice) and response rates (i.e., percentage
change in IOP from baseline) at 6 and 12 weeks in
treatment-naïve patients and patients previously treated
with monotherapy or combination therapy (i.e., switched).
Safety assessments included biomicroscopy, visual acuity,
ocular AEs, and the number of discontinuations due to
AEs. For each discontinuation, every effort was made to
contact the patient and document the outcomes.
All patients who received at least 1 dose of study
medication were included in the intent-to-treat and
safety populations. All individual hyperemia scores re-
corded for each grade (i.e., 0, +0.5, +1, +2, +3) were re-
ported as frequency counts and percentages for all
study visits, and the change from baseline was reported
at weeks 6 and 12. The treatment effect was analyzed
using a 2-sided McNemar test. Change and percentage
change in IOP from baseline at weeks 6 and 12 were
analyzed using the 2-sided Student paired t test. No statis-
tical analyses were conducted comparing treatment-naïve
and previously treated patients. Owing to the exploratory
nature of the study, no sample size calculation was carried
out.
Supplemental analyses of the occurrence and severity
of hyperemia produced by bimatoprost 0.01 %, as well as
its IOP-lowering effects, were conducted for subgroups of
patients who at baseline were receiving PGA or non-PGA
monotherapy, and latanoprost or travoprost monotherapy.
Results
Eleven centers participated in the study. The intent-to-treat/
safety population (N= 312) consisted of treatment-naïve
patients and previously treated patients (Fig. 1). Among the
latter subgroup, 91.1 % had been prescribed only 1 IOP-
lowering therapy (monotherapy or fixed-combination ther-
apy of any kind) at the time of enrollment. Most patients
completed the study, and discontinuations were due to ocu-
lar AEs, lost to follow-up, or other non-AE-related reasons
(Fig. 1).
Overall, 90.4 % of patients had a diagnosis of OAG.
Baseline characteristics were similar between treatment-
naïve and previously treated patients, except for the
diagnosis and medical comorbidities (Table 1). Among
previously treated patients, 83.0 % (n = 224) were receiv-
ing monotherapy at baseline (Table 1); 93.0 % were
switched to bimatoprost 0.01 % monotherapy because of
intolerance or insufficient IOP-lowering with previous
therapy.
At week 12, 29 (85.3 %) treatment-naïve patients with
available data had no hyperemia, compared with 36
(85.8 %) at baseline (Table 2). No severe cases were re-
ported in this group of patients at any visit (Table 2). In
the previously treated group, 170 (70.8 %) patients had
no hyperemia at week 12, compared with 201 (74.4 %) at
baseline (Table 2; Fig. 2a). There were no statistically sig-
nificant shifts in hyperemia severity from baseline in
either group (Fig. 2a) or in subgroups based on previous
use of non-PGA versus PGA monotherapy (Fig. 2b), and
latanoprost versus travoprost monotherapy (Fig. 2c).
Similarly, there were no statistically significant shifts in
Fig. 1 Patient disposition. AEs adverse events, ITT intent-to-treat
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hyperemia severity from baseline (P = 1.0000) in patients
previously treated with > 1 therapy (not shown).
In treatment-naïve patients, mean baseline IOP ± SD
was 18.0 ± 3.8 mm Hg. A statistically significant reduction
in mean IOP from baseline of approximately 20 % was ob-
served at weeks 6 and 12 (P < 0.0001; Fig. 3). In the
subgroup of patients who had a baseline IOP ≤ 21 mm Hg
(mean ± SD, 16.6 ± 2.3 mm Hg; n = 35; 83.3 %), the mean
IOP reduction from baseline was 2.8 mm Hg (P < 0.0001
at both timepoints) at both weeks 6 (16.2 %) and 12









Age, mean (SD), years 52.5 (13.7) 53.4 (14.5) 53.3 (14.3)
Gender, n (%)
Male 22 (52.4) 156 (57.8) 178 (57.1)
Female 20 (47.6) 114 (42.2) 134 (42.9)
Diagnosis, n (%)
OHT 9 (21.4) 21 (7.8) 30 (9.6)
OAG 33 (78.6) 249 (92.2) 282 (90.4)
Study eye, n (%)
Right 27 (64.3) 171 (63.3) 198 (63.5)
Left 15 (35.7) 99 (36.7) 114 (36.5)
IOP, mean (SD), mm Hg 18.0 (3.8) 17.8 (3.9) 17.9 (3.9)
Patients previously treateda, n (%) NA
PGA monotherapy 125 (46.3) 125 (40.1)
Non-PGA monotherapy 99 (36.7) 99 (31.7)
PGA fixed-combination therapy 5 (1.9) 5 (1.6)
Non-PGA fixed-combination
therapy
17 (6.3) 17 (5.4)
> 1 prior therapies 24 (8.9) 24 (7.7)
Patients with ≥ 1 medical
comorbiditiesb, n (%)
14 (33.3) 160 (59.3) 174 (55.8)
aMedications used at baseline included betaxolol, bimatoprost 0.03 %,
brimonidine, brimonidine/timolol, brinzolamide, brinzolamide/timolol,
carteolol, dorzolamide, dorzolamide/timolol, latanoprost, latanoprost/timolol,
timolol, and travoprost
bMedical comorbidities included asthma, diabetes, hypertension,
cardiovascular disease, pulmonary disease, periorbital changes due to previous
PGA therapy, and others
IOP intraocular pressure, NA not applicable, OAG open-angle glaucoma, OHT
ocular hypertension, PGA prostaglandin analog, SD standard deviation





Assessment visit Baseline Week 12 Baseline Week 12
Missing data, n (%) 0 8 (19.0) 0 30 (11.1)
Hyperemia grading, n (%)
0 (none, normal) 13 (31.0) 7 (20.6) 39 (14.4) 36 (15.0)
+0.5 (trace) 12 (28.6) 10 (29.4) 70 (25.9) 50 (20.8)
+1 (mild) 11 (26.2) 12 (35.3) 92 (34.1) 84 (35.0)
+2 (moderate) 6 (14.3) 5 (14.7) 57 (21.1) 59 (24.6)




Fig. 2 Shift in hyperemia severity grading from baseline at week 12
in (a) treatment-naïve and previously treated patients (P ≥ 0.2717 in
both groups, compared with baseline), (b) patient subgroups
previously treated with prostaglandin analog (PGA) or non-PGA
monotherapy (P ≥ 0.2295 in both groups, compared with baseline),
and (c) patient subgroups previously treated with latanoprost or
travoprost monotherapy (P ≥ 0.1185 in both groups, compared
with baseline)
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(16.6 %). In the subgroup who had a baseline IOP
> 21 mm Hg (mean ± SD, 24.9 ± 2.0 mm Hg; n = 7;
16.7 %), the mean IOP reduction from baseline reached
10.5 ± 4.2 mm Hg (P = 0.0154) at week 6 (41.0 %) and
10.0 ± 4.1 mm Hg (P = 0.0163) at week 12 (39.0 %).
In previously treated patients, mean IOP ± SD at base-
line was 17.8 ± 3.9 mm Hg, and the mean additional IOP
reduction from baseline (> 13 %) was also statistically
significant at both post-baseline visits despite the high
proportion of patients previously treated with PGA
monotherapy (P < 0.0001; Fig. 3; Table 1). Similar results
were observed in the patient subgroups previously treated
with PGA versus non-PGA monotherapy (Fig. 4a), as well
as those previously treated with latanoprost versus travo-
prost monotherapy (Fig. 4b). In patients who received > 1
therapy before switching to bimatoprost 0.01 %, mean
IOP ± SD at baseline was 18.4 ± 3.8 mm Hg, and the mean
additional IOP reduction from baseline was also statisti-
cally significant at weeks 6 (3.3 mm Hg; P = 0.0001) and
12 (2.4 mm Hg; P = 0.0093).
Overall, 26.2 % and 13.7 % of treatment-naïve and pre-
viously treated patients reported treatment-related AEs,
respectively (Table 3); all were ocular in nature, none
were serious, and conjunctival hyperemia was the most
frequent in both groups (Table 3). Consistent with these
results, more patients discontinued treatment owing to
AEs in the treatment-naïve and previously treated
groups (Table 3).
Discussion
The APPEALTaiwan study was designed to assess the tol-
erability and efficacy of bimatoprost 0.01 % in patients
with OHT or OAG (including NTG) evaluated in typical
clinical practice settings. The results demonstrate that
when administered once daily over 12 weeks, bimatoprost
0.01 % caused no significant shift in hyperemia severity
Fig. 3 Mean intraocular pressure (IOP) reduction at weeks 6 and 12




Fig. 4 Mean intraocular pressure (IOP) reduction at week 12 in (a)
patient subgroups previously treated with prostaglandin analog (PGA)
or non-PGA monotherapy, and (b) patient subgroups previously
treated with latanoprost or travoprost monotherapy. *P < 0.0001,
compared with baseline; †P < 0.0002, compared with baseline
Table 3 Summary of patients with adverse eventsa
Treatment-
naïve (n = 42)
Previously
treated (n = 270)
All
(N = 312)
All adverse events, n (%) 18 (42.9) 70 (25.9) 88 (28.2)
Treatment-related,
n (%)
11 (26.2) 37 (13.7) 48 (15.4)
Oculara 11 (26.2) 37 (13.7) 48 (15.4)
Ocular hyperemia 6 (14.3) 12 (4.4) 18 (5.8)
Dark circles
under the eyes
0 6 (2.2) 6 (1.9)
Eye pruritus 1 (2.4) 4 (1.5) 5 (1.6)
Decreased
lacrimation
1 (2.4) 4 (1.5) 5 (1.6)
Eye allergy 1 (2.4) 2 (0.7) 3 (1.0)
Ocular discomfort 1 (2.4) 1 (0.4) 2 (0.6)
Eye pain 1 (2.4) 0 1 (0.3)




6 (14.3) 15 (5.6) 21 (6.7)
aReported by > 2 % of patients
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from baseline in treatment-naïve and previously treated
patients, but produced statistically significant IOP lower-
ing from baseline in both groups.
At study end, hyperemia severity remained unchanged
or improved in ≥ 87 % of patients in both groups. More-
over, mean IOP reduction from baseline reached 19 % in
treatment-naïve patients, despite a low baseline mean
IOP (i.e., 18.0 ± 3.8 mm Hg). Although the subgroup of
patients with baseline IOP > 21 mm Hg and available
data on hyperemia at week 12 was small (n = 4), mean
IOP reduction from baseline reached 39 %, consistent
with data from other studies of bimatoprost 0.01 % in
treatment-naïve patients with baseline IOP > 21 mm Hg
[15, 38, 39, 43]. Similarly, bimatoprost 0.01 % provided
an additional 13 % reduction in mean IOP in previously
treated patients, compared with baseline, despite the
heterogeneity of this subgroup in terms of previous
treatment.
In the supplemental analyses based on previous treat-
ment, statistically significant reductions in mean IOP
from baseline were observed in patient subgroups
previously treated with non-PGA or PGA monotherapy,
latanoprost or travoprost monotherapy, or > 1 therapy
before switching to bimatoprost 0.01 %, but no signifi-
cant shifts in hyperemia severity from baseline were
observed in any of those subgroups.
Overall, our data indicate that treatment with bimato-
prost 0.01 % can significantly lower IOP in treatment-
naïve patients who have a low baseline IOP, as well as
patients who have achieved some degree of IOP lower-
ing with other therapies. These findings are consistent
with those of the multicenter, open-label, observational,
APPEAL Korea study of treatment-naïve [15] and previ-
ously treated [42] patients with OAG (including NTG)
or OHT evaluated in the Korean clinical setting. The
IOP-lowering efficacy and tolerability of bimatoprost
0.01 % observed herein also are consistent with the re-
sults of a 12-month, multicenter, randomized, double-
masked, controlled clinical trial of bimatoprost 0.01 % in
treatment-naïve and previously treated patients with ele-
vated IOP due to glaucoma or OHT [37]. Similarly, our
results are consistent with those of the 12-week, open-
label, multicenter, observational, Canadian CLEAR study
of treatment-naïve patients with OAG or OHT and ele-
vated IOP who were monitored in the clinical setting [38].
The overall percentage of patients with ocular AEs lead-
ing to discontinuation (6.7 %) recorded herein is consist-
ent with that reported in other studies (i.e., ≤ 5.4 %)
[15, 37–39, 44].
As age is a primary risk factor for OAG and the popula-
tion is aging across the globe, more patients are expected
to require monitoring and therapy in the near future [1],
making OAG an important clinical issue. In this regard, it
is noteworthy that the study population evaluated herein
had a relatively young mean age (53.3 years), compared
with that in other studies of bimatoprost 0.01 % (mean
range, 61.1–68.2 years) [37–39, 44]. In fact, mean age was
even lower than the 58.0 and 59.5 years reported in the
APPEAL Korea study of treatment-naïve [15] and previ-
ously treated patients [42], respectively, which included
patients with NTG. Whether this difference is indicative
of early onset or early detection is unknown at this time
and requires further investigation.
Potential limitations of the study include the open-label
design, lack of comparator, relatively short duration, and a
possible Hawthorne effect in patients who switched to
bimatoprost 0.01 % from a previous treatment [41], as well
as the fact that inter-observer differences could have
existed in the hyperemia grading despite use of a standard
photonumeric bulbar conjunctival hyperemia grading
scale. The absence of a washout period prior to initiation
of study treatment should also be considered, although it
was deliberately set to reflect typical clinical practice set-
tings. It is also noteworthy that all outcome variables were
assessed at 12 weeks, a timepoint at which no residual
carry-over effects from previous treatments are expected.
Conclusions
This study of patients with OAG (including NTG) or
OHT in the Taiwanese clinical setting showed that
bimatoprost 0.01 % provides significant IOP lowering
in treatment-naïve patients (regardless of baseline IOP),
as well as previously treated patients (even those with
relatively low IOP on other therapies), while causing no
significant changes in hyperemia from baseline.
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